NCT02609503 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02609503
Title	Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	UNC Lineberger Comprehensive Cancer Center
Indications	head and neck squamous cell carcinoma
Therapies	Pembrolizumab
Age Groups:	adult
Covered Countries	USA

Filter rows:

Showing 1 to 3 of 3 entries

Facility	City	State	Zip	Country	Details
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	United States	Details
John Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland	21231	United States	Details
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina	27599	United States	Details

Showing 1 to 3 of 3 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT02609503Clinical Trial Detail